Literature DB >> 22805691

Presentation and outcome of idiopathic thrombocytopenic purpura in a single Australian centre.

P Y-I Choi1, J E A Gordon, M Harvey, B H Chong.   

Abstract

Immune thrombocytopenia can be a therapeutic challenge with multiple first- and second-line treatment options. A change in idiopathic thrombocytopenic purpura (ITP) definition and classification in recent consensus guidelines suggests that past descriptions of ITP presentation and outcome may be outdated. In this single centre retrospective analysis of patients with thrombocytopenia from 1 January 2005 to 1 June 2010, 139 patients met current ITP diagnostic criteria. About 54/139 were new presentations of primary ITP. Six- and 24-month response rates were 39% and 30% respectively. About 26/54 patients did not require treatment at presentation: 15 were followed up for at least 6 months and none required treatment subsequently. These results suggest that almost half of all new primary ITP do not need treatment.
© 2012 The Authors. Internal Medicine Journal © 2012 Royal Australasian College of Physicians.

Entities:  

Mesh:

Year:  2012        PMID: 22805691     DOI: 10.1111/j.1445-5994.2012.02740.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  3 in total

1.  Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand.

Authors:  Philip Yi Choi; Eileen Merriman; Ashwini Bennett; Anoop K Enjeti; Chee Wee Tan; Isaac Goncalves; Danny Hsu; Robert Bird
Journal:  Med J Aust       Date:  2021-10-10       Impact factor: 12.776

2.  Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.

Authors:  Fabian Depré; Nasra Aboud; Beate Mayer; Abdulgabar Salama
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

3.  The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review.

Authors:  Kristy Purnamawati; Jamie Ann-Hui Ong; Siddharth Deshpande; Warren Kok-Yong Tan; Nihar Masurkar; Jackson Kwee Low; Chester Lee Drum
Journal:  Front Immunol       Date:  2018-06-04       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.